• 1. Novel isatin derivatives of podophyllotoxin: synthesis and cytotoxic evaluation against human leukaemia cancer cells as potent anti-MDR agents
  Lei Zhang,Fan Chen,Jing Wang,Yongzheng Chen,Zeguo Zhang,Ya Lin,Xinling Zhu RSC Adv. 2015 5 97816
• 2. Narrow-optical-gap π-conjugated small molecules based on terminal isoindigo and thienoisoindigo acceptor units for photovoltaic application
  Makoto Karakawa,Yoshio Aso RSC Adv. 2013 3 16259
• 3. Vinylene and benzo[c][1,2,5]thiadiazole: effect of the π-spacer unit on the properties of bis(2-oxoindolin-3-ylidene)-benzodifuran-dione containing polymers for n-channel organic field-effect transistors
  Thu Trang Do,Basanagouda B. Patil,Samarendra P. Singh,Soniya D. Yambem,Krishna Feron,Kostya (Ken) Ostrikov,John M. Bell,Prashant Sonar RSC Adv. 2018 8 38919
• 4. Recyclable (PhSe)2-catalyzed selective oxidation of isatin by H2O2: a practical and waste-free access to isatoic anhydride under mild and neutral conditions
  Lei Yu,Jianqing Ye,Xu Zhang,Yuanhua Ding,Qing Xu Catal. Sci. Technol. 2015 5 4830
• 5. Novel calamitic liquid crystalline organic semiconductors based on electron-deficient dibenzo[c,h][2,6]naphthyridine: synthesis, mesophase, and charge transport properties by the time-of-flight technique
  Ming-Cong Yang,Jun-ichi Hanna,Hiroaki Iino J. Mater. Chem. C 2019 7 13192

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Indoles and derivatives Indolines

Recent Advances in the Study of 6-Bromo-2,3-dihydro-1H-indole-2,3-dione (CAS: 6326-79-0): A Promising Scaffold in Medicinal Chemistry

The compound 6-bromo-2,3-dihydro-1H-indole-2,3-dione (CAS: 6326-79-0) has recently garnered significant attention in the field of medicinal chemistry due to its versatile pharmacological properties and potential applications in drug discovery. This heterocyclic scaffold, belonging to the indole-2,3-dione (isatin) family, has been extensively studied for its role as a key intermediate in the synthesis of bioactive molecules. Recent research highlights its utility in the development of novel therapeutic agents targeting various diseases, including cancer, neurodegenerative disorders, and infectious diseases.

One of the most notable advancements in the study of 6-bromo-2,3-dihydro-1H-indole-2,3-dione is its application in the design of kinase inhibitors. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that derivatives of this compound exhibit potent inhibitory activity against cyclin-dependent kinases (CDKs), which are critical regulators of the cell cycle. The bromo-substitution at the 6-position was found to enhance binding affinity to the ATP-binding pocket of CDK2, suggesting its potential as a lead compound for anticancer drug development.

In addition to its anticancer properties, 6-bromo-2,3-dihydro-1H-indole-2,3-dione has shown promise in the treatment of neurodegenerative diseases. A recent study in ACS Chemical Neuroscience reported that this scaffold can modulate the activity of monoamine oxidase B (MAO-B), an enzyme implicated in the pathogenesis of Parkinson's disease. The researchers synthesized a series of derivatives and evaluated their MAO-B inhibitory activity, identifying several compounds with nanomolar potency and high selectivity over MAO-A.

Another area of interest is the antimicrobial potential of 6-bromo-2,3-dihydro-1H-indole-2,3-dione. A 2022 study in European Journal of Medicinal Chemistry explored its efficacy against drug-resistant bacterial strains, including methicillin-resistant Staphylococcus aureus (MRSA). The study revealed that bromo-substituted isatin derivatives exhibit broad-spectrum antibacterial activity, with minimal cytotoxicity to mammalian cells. These findings underscore the potential of this scaffold in addressing the global challenge of antimicrobial resistance.

The synthetic versatility of 6-bromo-2,3-dihydro-1H-indole-2,3-dione has also been a focal point of recent research. A 2023 review in Organic & Biomolecular Chemistry summarized various synthetic routes to access this compound and its derivatives, highlighting the efficiency of palladium-catalyzed cross-coupling reactions for functionalization at the 6-position. These methodologies enable the rapid generation of diverse libraries of compounds for structure-activity relationship (SAR) studies.

In conclusion, 6-bromo-2,3-dihydro-1H-indole-2,3-dione (CAS: 6326-79-0) represents a highly promising scaffold in medicinal chemistry, with demonstrated applications in oncology, neurology, and infectious disease research. Continued exploration of its pharmacological properties and synthetic accessibility is expected to yield novel therapeutic agents with improved efficacy and safety profiles. Future studies should focus on optimizing the pharmacokinetic properties of its derivatives and evaluating their in vivo efficacy in preclinical models.

• 346-34-9(4-Fluoroindoline-2,3-dione)
• 391-12-8(7-(trifluoromethyl)-2,3-dihydro-1H-indole-2,3-dione)
• 97-36-9(2,4-Dimethylacetoacetanilide)
• 306325-13-3(6-bromo-5-methyl-2,3-dihydro-1H-indole-2,3-dione)
• 117-06-6(1-Amino-5-benzoylaminoanthraquinone)
• 345-32-4(5-(Trifluoromethyl)indoline-2,3-dione)
• 443-69-6(5-Fluoroisatin)
• 59-48-3(Oxindole)
• 317-20-4(7-fluoro-2,3-dihydro-1H-indole-2,3-dione)
• 93-68-5(N-(2-methylphenyl)-3-oxobutanamide)